Respiratory Biologics Market Report 2026

Respiratory Biologics Market Overview

• Respiratory Biologics market size has reached to $7.41 billion in 2025 • Expected to grow to $15.66 billion in 2030 at a compound annual growth rate (CAGR) of 16.1% • Growth Driver: Rise In Air Pollution Driving The Growth Of The Market Due To Increasing Health Risks And Demand For Targeted Therapies • Market Trend: Targeted Immune Therapies Supporting Innovation In Treatments For Chronic Lung Diseases • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Respiratory Biologics Market?

Respiratory biologics are a class of targeted medications derived from living organisms used to treat chronic respiratory diseases. These biologics typically target specific molecules in the immune system, such as interleukins (IL-4, IL-5, IL-13) or immunoglobulin E (IgE), to reduce inflammation and improve breathing. Respiratory biologics are often prescribed for patients with severe, uncontrolled respiratory conditions that do not respond well to standard treatments like inhaled corticosteroids and bronchodilators. The main disease indication of respiratory biologics is asthma, chronic rhinosinusitis, and hypereosinophilic syndrome. Asthma is a chronic inflammatory disease of the airways that causes breathing difficulties, wheezing, and coughing due to airway narrowing and hyperresponsiveness. The various routes of administrations include intravenous, and subcutaneous and are sold by different channels such as hospitals, specialty clinics, retail pharmacies, and mail order pharmacies.

What Is The Respiratory Biologics Market Growth Forecast?

The respiratory biologics market size is expected to see rapid growth in the next few years. It will grow to $15.66 billion in 2030 at a compound annual growth rate (CAGR) of 16.1%. The growth in the forecast period can be attributed to precision respiratory medicine growth, expansion of biologics pipelines, rising healthcare spending, improved reimbursement policies, unmet needs in severe respiratory disease. Major trends in the forecast period include rising adoption of targeted biologic therapies, expansion of severe asthma treatments, growth of biomarker-based patient selection, increasing use of injectable respiratory drugs, shift toward long-acting biologic agents.

Global Respiratory Biologics Market Segmentation

1) By Disease Indication: Asthma, Chronic Rhinosinasitis, Hypereosinophilic Syndrome 2) By Route Of Administration: Intravenous, Subcutaneous 3) By Sales Channel: Hospitals, Specialty Clinics, Retail Pharmacies, Mail Order Pharmacies Subsegments: 1) By Asthma: Severe Eosinophilic Asthma, Allergic Asthma, Non-Allergic Asthma 2) By Chronic Rhinosinasitis: Chronic Rhinosinusitis: Chronic Rhinosinusitis with Nasal Polyps, Chronic Rhinosinusitis without Nasal Polyps 3) By Hypereosinophilic Syndrome (HES): Idiopathic HES, Lymphocytic Variant HES, Myeloproliferative HES

What Is The Driver Of The Respiratory Biologics Market?

The rise in air pollution is expected to propel the growth of the respiratory biologics market going forward. Air pollution refers to the presence of harmful substances such as gases, particulate matter, and biological molecules in the Earth's atmosphere, which can negatively impact human health and the environment. Air pollution is increasing due to rising industrialization and urbanization, leading to higher emissions of pollutants from factories, vehicles, and construction activities. Respiratory biologics help combat the health effects of air pollution by providing targeted therapies that reduce inflammation and improve lung function in individuals exposed to airborne pollutants. For instance, in January 2025, according to the Environmental Protection Agency, a US-based government agency, the United States released over 66 million tons of pollutants into the atmosphere in 2023. Therefore, the rise in air pollution is driving the growth of the respiratory biologics industry.

Key Players In The Global Respiratory Biologics Market

Major companies operating in the respiratory biologics market are Sanofi S.A., AstraZeneca plc, GlaxoSmithKline plc, Regeneron Pharmaceuticals Inc., Novartis AG, F. Hoffmann-La Roche Ltd., Amgen Inc., Swedish Orphan Biovitrum AB, Teva Pharmaceutical Industries Ltd., AbbVie Inc., Pfizer Inc., Merck & Co. Inc., Bristol Myers Squibb Company, Johnson & Johnson, Boehringer Ingelheim International GmbH, Biogen Inc., Vertex Pharmaceuticals Incorporated, Glenmark Pharmaceuticals Ltd., Kiniksa Pharmaceuticals Ltd., Pieris Pharmaceuticals Inc.

Global Respiratory Biologics Market Trends and Insights

Major companies operating in the respiratory biologics market are focusing on developing innovative biologic therapies, such as targeted immune therapies for chronic respiratory diseases, to provide targeted treatments that reduce inflammation and improve lung function. Targeted immune therapies for chronic respiratory diseases are treatments that help control the body’s defense system to reduce swelling and breathing problems in long-term lung conditions. For instance, in September 2024, Sanofi S.A., a France-based pharmaceutical company, announced that the US Food and Drug Administration (FDA) approved Dupixent (dupilumab) as an add-on maintenance therapy for adults with inadequately controlled chronic obstructive pulmonary disease (COPD) who had an eosinophilic phenotype. This approval marked a significant milestone, as Dupixent became the first biologic medicine authorized in the US for treating this specific group of COPD patients.

What Are Latest Mergers And Acquisitions In The Respiratory Biologics Market?

In February 2024, GlaxoSmithKline plc, a UK-based pharmaceutical company, acquired Aiolos Bio for an undisclosed amount. With this acquisition, GSK aims to strengthen its respiratory and immunology portfolio by accessing Aiolos Bio’s innovative treatments for inflammatory and immune-mediated diseases. Aiolos Bio is a US-based company that focuses on developing biological therapies for respiratory and inflammatory diseases.

Regional Insights

North America was the largest region in the respiratory biologics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Respiratory Biologics Market?

The respiratory biologics market consists of sales of monoclonal antibodies (mAbs), interleukin inhibitors, and immunomodulators. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Respiratory Biologics Market Report 2026?

The respiratory biologics market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the respiratory biologics industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.